Efficacy and safety of niraparib combined with anlotinib maintenance retreatment in platinum-sensitive recurrent ovarian cancer patients who previously received PARP inhibitor: An open-label, single-arm, prospective, exploratory phase II study

A series of high-level evidence-based medical evidence has clarified that Poly ADP ribose polymerase (PARP) inhibitors as maintenance therapy have significantly prolonged progression-free survival (PFS) in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer who have achieved complete response (CR) or partial response (PR) after platinum-based chemotherapy. With the wide application of PARPi, the possibility of PARPi rechallenge in maintenance settings for patients who have received prior PARPi therapy has become an increasing concern in clinical practice. This study will investigate the efficacy and safety of niraparib combined with anlotinib maintenance treatment in patients with platinum-sensitive recurrent (PSR) non-mucinous EOC who have previously received maintenance therapy with one PARPi.